This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
CRA published a report for Pharmaceutical Care Management Association on the potential effects on proposed changes to the definition of Medicare Part D prices. To read the report, click the link below.
Inspiring stakeholders to take action on antimicrobial resistance (AMR) starts with communicating the current and future burden of...
RADAR contains all orphan drugs (ODs) that received European Medicines Agency (EMA) marketing authorisation between July 1, 2013, and September 30, 2024. For...
Abhishek Kumar presents his poster titled “Top Trends Affecting the Vaccines Market and their Implications on Access Policy and Public Health...
CRA is a proud sponsor of the conference focusing on the intersection of intellectual property and the biopharmaceutical industry, and will explore the law,...
